Hs-CRP and HOMA-IR: Include them in the MASLD definition, or treat them as mediators between MASLD and atherosclerotic cardiovascular disease?
Journal of Hepatology · 2025-01 · 82 (1) · e26-e28
DOI: 10.1016/j.jhep.2024.08.005 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Hepatology, 2025-01. Verfasst von Heng Wan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, …. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China.
- Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China. Electronic address: wnj486@126.com.
- Department of Endocrinology and Metabolism, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China. Electronic address: sjiesy@smu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wan, H., Gui, Z., Liu, L., Wang, N., & Shen, J. (2025). Hs-CRP and HOMA-IR: Include them in the MASLD definition, or treat them as mediators between MASLD and atherosclerotic cardiovascular disease?. Journal of Hepatology, 82(1), e26-e28. https://doi.org/10.1016/j.jhep.2024.08.005
Vancouver
Wan H, Gui Z, Liu L, Wang N, Shen J. Hs-CRP and HOMA-IR: Include them in the MASLD definition, or treat them as mediators between MASLD and atherosclerotic cardiovascular disease?. Journal of Hepatology. 2025;82(1):e26-e28. doi:10.1016/j.jhep.2024.08.005
BibTeX
@article{Wan2025,
author = {Wan, Heng and Gui, Zihao and Liu, Lan and Wang, Ningjian and Shen, Jie},
title = {Hs-CRP and HOMA-IR: Include them in the MASLD definition, or treat them as mediators between MASLD and atherosclerotic cardiovascular disease?},
journal = {Journal of Hepatology},
year = {2025},
volume = {82},
number = {1},
pages = {e26--e28},
doi = {10.1016/j.jhep.2024.08.005}
}
EUVIMED